Keyword Tag Sort by

Avastin News (35 articles)



Roche data showed that people with metastatic colorectal cancer lived longer when they continued on Avastin plus chemotherapy

First phase III study to appraise continued Avastin through different lines of therapyRoche (SIX: RO, ROG; OTCQX: RHHBY) announced  results from ML18147, a phase III study in metastatic colorectal cancer (mCRC) that evaluated Avastin (bevacizumab) continued with second-line chemotherapy...

Published on 4 June 2012, 01:47


Roche will report new data on important progress for people with advanced cancers at ASCO 2012

First pivotal Phase III data on Roche’s antibody-drug conjugate trastuzumab emtansine (T-DM1) in advanced HER2-positive metastatic breast cancer Phase III data on Avastin in advanced colorectal and ovarian cancers Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the company...

Published on 16 May 2012, 03:08


Study shows Avastin has similar effect to Lucentis in treating most common cause of blindness in the developed world

The one year results from a study into whether two drug treatments (Lucentis and Avastin), are equally effective in treating neovascular or wet age-related macular degeneration (wet AMD), have been reported today at an international research meeting in Fort Lauderdale, Florida.* The findings...

Published on 8 May 2012, 13:49


Roche highlights data that demonstrate a range of new approaches to target breast, skin and lung cancers at 2011 European Multidisciplinary Cancer Congress

Data show greater understanding of disease pathways and personalising treatments for people with cancer.Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that encouraging data on its investigational and approved medicines will be presented at the 2011 European Multidisciplinary Cancer Congress...

Published on 19 September 2011, 03:12


NIH Study Finds Avastin and Lucentis are Equally Effective in Treating Age-Related Macular Degeneration

(ATLANTA) - Emory Eye Center and other study centers have been a part of a two-year national clinical trial evaluating two drugs for age-related macular degeneration (AMD). Results from the first year of a trial among 48 eye institutions show that Avastin (bevacizumab) - a drug approved to...

Published on 29 April 2011, 13:54


Roche gains positive CHMP opinion for the combination of Avastin with Xeloda as a first-line treatment for metastatic breast cancer in Europe

Approval would allow combination of Avastin with paclitaxel or Xeloda, offering more choice to physicians and patients.Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an extension to the Avastin...

Published on 15 April 2011, 08:55


European Commission continues to support Avastin in combination with paclitaxel as an effective treatment option for women with metastatic breast cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission confirmed that Avastin (bevacizumab) in combination with paclitaxel will remain a treatment option for women with metastatic breast cancer in Europe. The decision follows recent recommendations made by the...

Published on 2 March 2011, 08:43


Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer

Avastin study in recurrent, platinum-sensitive ovarian cancer showed women lived significantly longer without their disease getting worse.Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy...

Published on 8 February 2011, 05:19


Roche provides update on Avastin for metastatic breast cancer following reviews in Europe and the United States

In the European Union, Avastin confirmed as a valuable treatment option in combination with paclitaxel In the United States, the company will request a hearing to maintain Avastin as a treatment option for metastatic breast cancerBasel, 16 December 2010 -- Roche confirmed that following...

Published on 16 December 2010, 11:04


Roche reports positive data for Avastin in ovarian cancer and T-DM1 in breast cancer

Encouraging new data released at ESMO congress Ovarian cancer: Data from second positive phase III study of Avastin (ICON7) add further evidence to the potential of Avastin in ovarian cancer where there have been few major treatment advances in the past decade1. Metastatic breast...

Published on 11 October 2010, 13:35


Avastin shows longest overall survival for patients with adenocarcinoma, the most common type of advanced lung cancer

This update outlines data from a preplanned analysis of the pivotal E4599 study in patients with non-small cell lung cancer (NSCLC), published in the Journal of Thoracic Oncology. The analysis looked at the impact of treatment with Avastin® (bevacizumab) in combination with...

Published on 6 August 2010, 03:01


Large ‘real-world’ study shows Avastin-based therapy extends survival beyond fourteen months in patients with advanced lung cancer

Avastin benefits demonstrated in combination with a wide range of chemotherapies and in a broad patient population.New data show that Avastin (bevacizumab) based therapy provides a median overall survival (OS) of 14.6 months with a range of chemotherapies routinely used in clinical practice...

Published on 21 July 2010, 03:49


Second phase III study showed Avastin-containing regimen helped women with ovarian cancer live longer without their disease getting worse

Study of Avastin in combination with standard chemotherapy, followed by continued use of Avastin,met primary endpoint of improving progression-free survival in women with ovarian cancer.Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a second large, phase III, international study showed...

Published on 2 July 2010, 11:00


Phase III study showed Avastin-based regimen helped women with advanced ovarian cancer live longer without their disease worsening

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent...

Published on 6 June 2010, 10:35


Roche Provides Update on Phase III Study of Avastin in Men With Late Stage Prostate Cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the topline results of a phase III trial led by the US Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin (bevacizumab) in combination with docetaxel chemotherapy and prednisone in...

Published on 12 March 2010, 03:25


Avastin Phase III Study Shows Positive Results in Women With Advanced Ovarian Cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a phase III study showed the combination of Avastin (bevacizumab) and chemotherapy followed by maintenance use of Avastin increased the time women with advanced ovarian cancer lived without their disease worsening (progression-free survival...

Published on 25 February 2010, 05:39


Phase III Study of Avastin plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the topline results from a global phase III trial investigating the use of Avastin (bevacizumab) in combination with Xeloda (capecitabine) or fluorouracil and cisplatin chemotherapy in patients with inoperable, advanced or metastatic gastric...

Published on 23 February 2010, 05:18


New real world Avastin data from over 3,200 metastatic colorectal cancer patients confirms survival benefit beyond 2 years

2 large studies confirm Avastin’s role as a standard of care in metastatic colorectal cancer.New data from two large studies observing the routine use of Avastin-based therapy in more than 3,200 patients will be announced showing impressive treatment benefits in a non-selected patient...

Published on 21 January 2010, 03:11


From Cancer Cell To Brain Tumor

Metastasis formation revealed in detail and real time.Up to 25% of cancer patients develop metastases in the brain – often long after successful treatment of the primary tumor. In almost all such cases, the prognosis is poor. The mechanisms responsible for the appearance of brain metastases...

Published on 21 December 2009, 10:34


Important progress in treatment of early and late stage breast cancer with Herceptin, Avastin and T-DM1

Roche to present new results that could offer a better future to women with early and very advanced breast cancer, at the CTRC-AACR San Antonio Breast Cancer Symposium.Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new 5 year follow-up data from two pivotal studies with Herceptin®...

Published on 9 December 2009, 04:44


image